Estimated reproduction numbers (top, blue dots) and vaccine efficacies (bottom, gray dots) per school, with associated 95% credible intervals (cf. Table 3).

<p> Note that estimated vaccine efficacy is consistently high in schools with high exposure (schools 1–6), but cannot be estimated with any precision in schools with low exposure (schools 8–10).</p

Overview of the analyses per school (cf. Figure 3).

<p>The table shows the estimates of the basic reproduction number, vaccine efficacy, and critical vaccination coverage. Estimates are represented by posterior medians with 95% credible intervals.</p

Estimates of vaccine efficacy by the cohort method, i.e. as 1 minus the relative risk of infection in vaccinated versus unvaccinated persons ().

<p>Estimates are represented by posterior medians with 95% credible intervals. See text for details.</p

Estimates of vaccination coverage and attack rate per school when assuming common epidemiological parameters across schools (baseline scenario).

<p>Estimates are represented by posterior medians with 95% credible intervals.</p

Summary statistics of the study population.

<p>The column ‘number infected’ shows the possible range of actual infections, ranging from the number known to be infected to the sum of this number and the number of persons with unknown infection status. Vaccination coverages and attack rates are calculated using persons with known vaccination status (vaccination coverage), and known vaccination and infection status (attack rates). See <a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1003061#pcbi.1003061.s001" target="_blank">Tables S1</a>, <a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1003061#pcbi.1003061.s002" target="_blank">S2</a> for the complete data.</p>*<p>: averaged over schools.</p

Relation between vaccination coverage and overall attack rate in the baseline scenario.

<p>The figure shows the medians of the posterior vaccination coverages versus posterior attack rates in the ten schools (blue dots), the deterministic final size attack rate using the posterior medians of the basic reproduction number and vaccine efficacy (dotted line), and the results of simulations in populations of size 200 using samples from the posterior distributions of the basic reproduction number and vaccine efficacy (black line: median; grey area: 2.5%–97.5% percentiles). See text for details.</p

Maximum parsimony tree based on the HBV S-region sequence of acute cases of HBV infection (n = 894), by most probable mode of transmission and gender, in the Netherlands, 2004–2010, and selected reference strains (n = 19).

<p>Maximum parsimony tree based on the HBV S-region sequence of acute cases of HBV infection (n = 894), by most probable mode of transmission and gender, in the Netherlands, 2004–2010, and selected reference strains (n = 19).</p

a–c. Genotype distribution by year of reporting of acute HBV infections, the Netherlands, 2004–2010. a. Cases acquired heterosexually by men and women (n = 300); b. Cases with an unknown route of transmission acquired by men and women (n = 226) c. Cases acquired by men who have sex with men (n = 305).

<p>a–c. Genotype distribution by year of reporting of acute HBV infections, the Netherlands, 2004–2010. a. Cases acquired heterosexually by men and women (n = 300); b. Cases with an unknown route of transmission acquired by men and women (n = 226) c. Cases acquired by men who have sex with men (n = 305).</p

Characteristics of the selective HBV vaccination programme for behavioural high-risk groups, The Netherlands, 1998–2010.

<p>Anti-HBc = antibody to the hepatitis B core antigen; CI = Confidence interval; HBsAg = hepatitis B surface antigen; STD = sexually transmitted disease.</p>†<p>Heterosexuals with frequent partner changes were no longer included in the programme from 2007 onwards.</p>‡<p>Proportion of the first vaccinations given at different locations, in percentages. Note: information about the vaccine location was missing for 3856 vaccinations.</p>§<p>Outreach locations included bars and saunas frequented by MSM, shelters for homeless people, and commercial sex worker locations.</p>¶<p>Prevalence was calculated by dividing the number of patients with a positive test by the total number with a test result.</p>∥<p>Compliance is defined as the proportion of those susceptible at the first vaccination completing three doses. Data up to 30 June 2011 were included.</p

Seroprevalence of the low vaccination coverage sample.

<p>Age specific seroprevalence of mumps antibodies of the low vaccination coverage sample (LVC) from the Pienter1 (red line) and Pienter2 (blue line) study.</p